bioprinting technology News
-
Bioprinting: Poietis announces the award of a third new major European patent
Poietis, 4D Bioprinting company, announces the issuance by the European Patent Office of a third patent covering its bioprinting technology: Patent No. EP3233499 entitled «Laser printing method and device for implementing said method», which covers in particular the process of bioprinting upwards, previously delivered in France, and in Europe on March 21st, 2019. As a reminder ...
By Poietis
-
McEwen Stem Cell Institute at the University Health Network (UHN) is a global leader in stem cell research and regenerative medicine
Vancouver, BC, Canada - November 30, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, is pleased to announce a research agreement with the University Health Network (UHN). Through this collaboration, Aspect Biosystems will combine its bioprinting technology with UHN’s protocols for differentiating stem ...
-
CELLINK and the University of California, San Diego Partner to Open a 3D Bioprinting Centre of Excellence
CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence. This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug ...
By CELLINK
-
CELLINK Announces CELLINK Vivoink: Our First Medical-Grade Bioink
CELLINK, a global leader in bioprinting technologies, is proud to announce a pioneering innovation in the field of regenerative medicine and tissue engineering with the launch of CELLINK Vivoink, the first-ever medical-grade bioink specially designed to support researchers on their clinical translational journey. CELLINK Vivoink is optimized for superior printability, mechanical stability, and ...
By CELLINK
-
Servier and Poietis announce scientific partnership in 4D bioprinting of liver tissues
Servier, an independent international pharmaceutical company, and Poietis, a leader in the production of living bioprinted tissues, have announced a scientific partnership to use Poietis’s 4D bioprinting technology for the development and production of liver tissues. This partnership seeks to improve the detection of drug-induced liver lesions as early as the preclinical trial phase. ...
By Poietis
-
Prellis Biologics Announces Collaboration with Sanofi
Prellis Biologics, Inc. (Prellis), a Bay Area biotherapeutics company, announced today that it has entered into a collaboration and license option agreement with Sanofi S.A. focused on the discovery of antibodies with Prellis’ first-in-class external human immune system (EXIS). The collaboration leverages Prellis’ ability to engineer fully-human lymph node organoids (LNOs™) and ...
-
VIVAX BIO, 3D Bioprinting Solutions, and partners complete the first cultured meat biofabrication experiment on board the ISS.
3D Bioprinting Solutions biotechnology laboratory, Meal Source Technologies, as well as Aleph Farms and Finless Foods, are proud to announce successful result of the joint project which involved magnetic biofabrication of bovine, mummichog and rabbit myoblast/fibroblast constructs in order to lay the groundwork for renewable protein sources for long term manned missions. Additionally, results of ...
-
Poietis signs a clinical research collaboration contract with the Assistance Publique – Hôpitaux de Marseille (AP-HM) to prepare the first clinical trial of a bioprinted skin.
Poietis, leading bioprinting company, and the « Assistance Publique – Hôpitaux de Marseille » (AP-HM) announced today that they have entered into a partnership through the signature the 20th of January of a clinical research collaboration contract on a bioprinted tissue engineering product. The objective of this agreement is to carry out within two years a Phase I clinical ...
By Poietis
-
BIOLIFE4D Names Pharmaceutical Veteran Kate Lewis as President
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has named Kate Lewis as President of the company. She joined BIOLIFE4D full time in early 2019 in a market and business development role before being elevated as the first female executive in Company history. Lewis brings more than 25 years of experience and ...
By BIOLIFE4D
-
Poietis and Prometheus, division of skeletal tissue engineering of KU Leuven, enter into a Collaborative Research Agreement focused on 3D Bioprinting for skeletal ATMPs.
Poietis, leading bioprinting company and Prometheus, Division of Skeletal Tissue Engineering at KU Leuven, entered into a 2-years Collaborative Research Agreement focused on high-precision 3D Bioprinting of tissue engineered Advanced Therapeutic Medicinal Products (ATMPs) for skeletal regeneration. Prometheus focuses on the bench-to-bedside clinical translation of increasingly ...
By Poietis
-
Poietis and Assistance Publique – Hôpitaux de Marseille (AP-HM) annouce the first installation of a 3D bioprinting platform for manufacturing implantable biological tissues in hospitals
The installation of the NGB (Next-Generation Bioprinting) robotic bioprinting platform developed by Poietis in the Advanced Therapy Medicinal Product (ATMP) manufacturing area of the Hôpital de la Conception represents a world premiere and opens up very promising perspectives in regenerative medicine. The objective is now to start the first clinical trial of a 3D printed ...
By Poietis
-
Poietis announces formation of Scientific Advisory Board and appoints two first prominent Regenerative Medicine experts
Poietis, 4D Bioprinting company, announces formation of Scientific Advisory Board (SAB) and appointment of two first prominent Scientists in Regenerative Medicine. The SAB will serve as a key strategic resource to Poietis as the company expands capabilities of Next- Generation Bioprinting (NGB) platform to therapeutic applications and develops first implantable tissues such as a ...
By Poietis
-
3D Bioprinting Solutions and URSC Cooperation Agreement - The Development of a Bioprinter for Space Applications
3D Bioprinting Solutions, a resident company of Skolkovo Innovation Center has entered into a cooperation agreement with URSC (Unified Rocket and Space Corporation, a member of ROSCOSMOS State Corporation), aiming to create a unique bioprinter capable of magnetic biofabrication of tissue and organ constructs in zero-gravity at the International Space Station (ISS). It was signed by the URSC ...
-
Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes
Carcinotech and CELLINK are pleased to announce a collaborative partnership to develop and commercialize protocols for the biofabrication of 3D bioprinted tumor models based on cancer cell lines that improve accuracy and rapidly speed up drug development processes, driving down development costs and enabling an improved output. The protocols will be available for use on the BIO CELLX system ...
By CELLINK
-
BICO acquires Allegro 3D, adding new light-based 3D bioprinting technology – complementing the existing offering of application tailored products
Adding Allegro 3D to the portfolio enables BICO Bioprinting to strengthen its position as the global leader in providing 3D bioprinters. BICO has a robust portfolio of bioprinters, utilizing extrusion based, 2PP and DLP technologies. BICO has acquired all the shares in San Diego-based Allegro 3D Inc. (“Allegro 3D”) for an up-front enterprise value of USD 6 million. Additionally, ...
-
BIOLIFE4D Becomes First U.S. Company to Successfully Demonstrate Ability to 3D Bioprint a Mini Human Heart
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has successfully demonstrated its ability to 3D bioprint a mini human heart, a significant step toward its goal of producing a full-sized human heart viable for transplant. The scientific milestone was accomplished at the Company’s research facility at ...
By BIOLIFE4D
-
3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors
3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced the appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to its Board of Directors. Dr. Barer is the former CEO and Chairman of Celgene and currently serves as Chairman of Teva Pharmaceuticals. Dr. Slawin, Founder and Managing Partner of Rapha Capital Management, previously founded ...
-
Stefan Blomsterberg appointed as new CEO of Cellink Bioprinting AB
Stefan Blomsterberg has been appointed as the new CEO of CELLINK. Cecilia Edebo, current CEO, requested earlier this year to resign from her position to pursue a new career opportunity outside the BICO Group. At the time of her resignation, a recruitment process was initiated which concluded in the appointment of Stefan Blomsterberg. Stefan Blomsterberg (born 1964) brings 20+ years of experience ...
By CELLINK
-
CELLINK and Ossiform Enter a Strategic Partnership to launch Ossi Ink, a printable bioink based on Ossiform’s P3D Bone material
CELLINK and Ossiform have entered a strategic partnership to join forces to commercialize a ready-to-print bioink based on Ossiform’s existing biomaterial. Sales of the material will begin in 2024 and will be distributed co-exclusively through CELLINK’s commercial channels. Bone regeneration is one of the fastest growing research disciplines, given the massive impact it can have on ...
By CELLINK
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you